An Open-label, Multicenter Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
Latest Information Update: 02 Sep 2025
At a glance
- Drugs Adebrelimab (Primary) ; Bevacizumab (Primary) ; SHR 8068 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 20 Jun 2024 Status changed from not yet recruiting to recruiting.
- 07 Jul 2022 New trial record